Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)

NCT03019588 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

94

Enrollment

INDUSTRY

Sponsor class

Stopped Business Reasons

Conditions

Gastric Neoplasms
Gastroesophageal Junction Adenocarcinoma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Paclitaxel

Sponsor

Merck Sharp & Dohme LLC